2026.02.01 本文字数：3133，阅读时长大约5分钟 作者 |第一财经 王方然 1月30日，第一财经从香港证监会获悉，近期监管机构已通过通函要求上市保荐人迅速开展内部检讨， 并纠正招股文件准备中出现的严重缺失，包括文件质量不足、保荐人可能存在的失当行为及其资源管理 重大失误等。截至2025年12月31日，已有16宗港股上市申请被暂停审理。 2025年，港股IPO数量与募资额同比大幅跃升，排队企业已突破300家，市场热度持续攀升。然而，申 报文件质量下滑、保荐人资源不足、人才争夺激烈、费率竞争加剧等问题也随之显现。为此，此次香港 证监会在通函中表示，将密集推出多项针对性整改措施，涵盖从严审核标准、强化保荐人员与项目匹配 度披露要求、设定人员负荷上限等方面。 业内人士指出，随着2026年可能到来的新一轮IPO高峰及潜在的限售股解禁压力，香港资本市场正步入 一段机遇与挑战并存的关键时期。 上市激增引发质量隐忧 香港证监会在近期通函中指出，高度关注2025年新股申请激增期间暴露的问题，包括部分上市文件存在 严重缺失、保荐人可能行为失当及其资源管理出现重大疏漏。 第一财经注意到，2025年香港IPO市场呈现井喷 ...

Core Viewpoint - The Hong Kong Securities and Futures Commission (SFC) has mandated a review of IPO application processes due to significant deficiencies in the quality of listing documents and potential misconduct by sponsors, amidst a surge in IPO applications and fundraising in 2025 [3][4][5]. Group 1: IPO Market Overview - In 2025, the Hong Kong IPO market saw a significant increase, with 102 companies going public, compared to 73 in the previous year, and total fundraising reaching HKD 238.2 billion, a 246% increase year-on-year [5]. - As of December 2025, there were over 319 IPO applications pending, indicating a backlog that exceeds the capacity of some investment banks [5][11]. - The market is expected to remain active in 2026, with predictions of continued strong fundraising, potentially exceeding HKD 300 billion [12]. Group 2: Regulatory Concerns - The SFC has expressed concerns over the declining quality of IPO application documents, including issues with drafting quality and compliance with regulatory feedback [6][9]. - There is a noted reliance on external professionals by sponsors, which raises questions about their qualifications and the overall quality of the IPO process [6][7]. - The SFC has identified that some sponsors are prioritizing transaction volume over quality control, which is critical for maintaining market integrity [7][10]. Group 3: Remedial Measures - The SFC has introduced several corrective measures aimed at improving IPO application quality, including stricter review standards and requirements for sponsors to assess their resource capabilities [9][10]. - Sponsors are required to submit a resource management plan if they have personnel overseeing six or more IPO projects simultaneously [10]. - Enhanced disclosure requirements for sponsors regarding the matching of personnel to projects have been implemented to ensure accountability [9][10]. Group 4: Market Dynamics and Risks - The competition among brokers for IPO shares has led to a decrease in underwriting fees, which fell to a record low of 1.5% in 2025, impacting their ability to invest in human resources [7][10]. - The upcoming release of lock-up shares in 2026 may pose risks to the market, as historical patterns show that significant unlock events often coincide with market downturns [12][13].

1月30日，第一财经从香港证监会获悉，近期监管机构已通过通函要求上市保荐人迅速开展内部检讨， 并纠正招股文件准备中出现的严重缺失，包括文件质量不足、保荐人可能存在的失当行为及其资源管理 重大失误等。截至2025年12月31日，已有16宗港股上市申请被暂停审理。 2025年，港股IPO数量与募资额同比大幅跃升，排队企业已突破300家，市场热度持续攀升。然而，申 报文件质量下滑、保荐人资源不足、人才争夺激烈、费率竞争加剧等问题也随之显现。为此，此次香港 证监会在通函中表示，将密集推出多项针对性整改措施，涵盖从严审核标准、强化保荐人员与项目匹配 度披露要求、设定人员负荷上限等方面。 业内人士指出，随着2026年可能到来的新一轮IPO高峰及潜在的限售股解禁压力，香港资本市场正步入 一段机遇与挑战并存的关键时期。 上市激增引发质量隐忧 近期香港市场监管机构已通过通函要求上市保荐人迅速开展内部检讨 香港证监会在近期通函中指出，高度关注2025年新股申请激增期间暴露的问题，包括部分上市文件存在 严重缺失、保荐人可能行为失当及其资源管理出现重大疏漏。 第一财经注意到，2025年香港IPO市场呈现井喷态势。Choice数据显示 ...

医药周报 20260130 从 JPM 大会挖掘 FIC 靶点三期数据验证节点 glmszqdatemark 医药行情回顾&分析&近期判断 周专题：从 JP Morgan 大会看 2026 MNC 密集验证新靶点 风险提示：1）医保、集采政策导致价格不及预期；2）临床进度或上市时间不及预期；3）行业竞争 格局的不确定性；4）地缘政治风险；5）下游投融资及需求复苏不及预期。 2026 年 02 月 01 日 推荐 维持评级 [Table_Author] | 分析师 张金洋 | | --- | | 执业证书： S0590525120012 | | 邮箱： zhangjinyang@glms.com.cn | | 分析师 胡偌碧 | | 执业证书： S0590525120011 | | 邮箱： huruobi@glms.com.cn | | 分析师 王彦迪 | | 执业证书： S0590525120015 | | 邮箱： wangyandi@glms.com.cn | 相对走势 -10% 7% 23% 40% 2025/2 2025/8 2026/1 医药 沪深300 相关研究 本公司具备证券投资咨询业务资格，请务 ...

Investment Rating - The report gives a "Buy" rating for the company, with a target price of 23.37 CNY based on a PE valuation of 57 times for 2026 [3][6]. Core Insights - The company is expected to benefit from a dual-driven strategy of traditional Chinese medicine (TCM) and chemical drugs, with a gradual clearance of the impact from centralized procurement on TCM business. The innovative drug pipeline is entering a harvest phase, with projected net profits for 2025-2027 being 290 million, 350 million, and 410 million CNY respectively, corresponding to EPS of 0.34, 0.41, and 0.48 CNY [3][9]. Summary by Sections 1. Dual-Driven Strategy of TCM and Chemical Drugs - The company has a rich product layout and maintains stable performance, with a focus on eye care, cardiovascular, respiratory, and digestive diseases. Revenue for the first three quarters of 2025 was 1.89 billion CNY, a decrease of 1.0% year-on-year, while net profit attributable to the parent company was 250 million CNY, an increase of 68.4% [13][9]. - The core TCM product, Compound Thrombus-Relieving Capsule, is a unique original formulation with a leading market share in the domestic ophthalmic TCM sector. The impact of centralized procurement is gradually being digested, and sales are expected to stabilize [9][10]. 2. Innovative Product Data and Growth Potential - The company has multiple innovative products entering commercialization or late-stage clinical trials. The PB2-targeted RNA polymerase inhibitor, Anladiwei Tablets, was approved in May 2025 for treating adult uncomplicated influenza, showing competitive advantages over Oseltamivir [9][27]. - The GLP-1/GIP dual-target drug RAY1225 for obesity and diabetes has entered Phase III clinical trials, with promising results indicating better weight loss efficacy compared to existing treatments [27][29]. 3. Financial Forecast and Investment Recommendations - The company’s revenue is projected to recover, with expected revenues of 2.803 billion, 3.126 billion, and 3.447 billion CNY for 2025, 2026, and 2027 respectively, reflecting growth rates of 13.6%, 11.5%, and 10.3% [5]. - The report emphasizes the importance of innovation and performance assessment, with an employee stock ownership plan launched in 2024 to incentivize core personnel [23][24].

Group 1 - The core conclusion indicates that in Q4 2025, the allocation of Hong Kong stocks by actively managed equity public funds has decreased, with a decline in the proportion of funds overweighting Hong Kong stocks [1][10] - The total size of actively managed equity public funds eligible to invest in Hong Kong stocks in Q4 2025 is 20,356 billion, accounting for 52.2% of the total actively managed equity fund size, down from 52.4% in Q3 2025 [10] - The market value of Hong Kong heavy stocks held by actively managed equity public funds in Q4 2025 is 3,121 billion, which is a decrease from 3,950 billion in Q3 2025 [10][11] Group 2 - In terms of industry allocation, actively managed equity public funds have increased their exposure to cyclical financial sectors while reducing exposure to technology and consumer sectors in Q4 2025 [2][19] - The sectors with increased allocation include non-ferrous metals (6.8%, up 2.3 percentage points), non-bank financials (5.1%, up 3.2 percentage points), and oil and petrochemicals (3.5%, up 2.1 percentage points) [19][26] - The sectors with reduced allocation include consumer discretionary retail (11.0%, down 2.2 percentage points), hardware equipment (3.0%, down 2.0 percentage points), and semiconductors (7.6%, down 2.0 percentage points) [19][26] Group 3 - The concentration of the top ten heavy stocks held by actively managed equity public funds has decreased, with their combined holding percentage in Q4 2025 being 49.7%, down from 54.0% in Q3 2025 [3][28] - The top three heavy stocks remain consistent with Q3 2025, including Tencent Holdings (holding size of 578 billion, accounting for 18.5%), Alibaba (310 billion, 10.0%), and SMIC (187 billion, 6.0%) [3][28]

Group 1 - In January 2026, nearly 660 private equity firms participated in A-share company research activities, with a total of over 1700 research instances [1][2] - The computer, machinery, pharmaceutical biology, and electronics sectors were the most focused on by private equity firms, with notable fund managers like Feng Liu from Gao Yi Asset and Zhu Liang from Dan Yi Investment attending technology stock research [1][2] - Despite significant gains in the technology sector in 2025, industry trends and corporate profitability indicate that the sector has not yet reached a "bubble stage," particularly in semiconductors and AI applications [1] Group 2 - A total of 659 private equity firms covered 332 A-share companies across 28 primary industries in January 2026, with 48 companies receiving more than 10 research visits [2] - The computer industry had 30 companies receiving research with a total of 296 instances, while the machinery equipment sector had 44 companies with 228 instances [3][4] - The pharmaceutical biology and electronics sectors also saw significant research activity, each exceeding 190 instances, with the electronics sector having the highest number of companies at 48 [4] Group 3 - Notable private equity fund managers showed interest in technology, with Feng Liu attending a research event for Hikvision, focusing on AI application advancements and robotics [5] - Zhu Liang from Dan Yi Investment researched Tongfu Microelectronics, which is positioned to benefit from the rapid development of domestic AI computing chips [6] - The AI industry is viewed as a key investment theme for 2026, with a shift towards practical applications and a growing demand for general-purpose GPUs and basic semiconductor equipment [7][8]

Market Performance - Hang Seng Index and the National Enterprises Index rose by 0.5% and 0.4% respectively, while the Hang Seng Tech Index fell by 1.0%[1] - Major sectors such as banking, insurance, precious metals, and oil showed strong performance recently[1] - Market anticipates regulatory easing for property developers, leading to a rise in many mainland property stocks[1] Macroeconomic Indicators - Hong Kong welcomed nearly 50 million visitors last year, a 12% increase from 2024, with mainland visitors accounting for 38 million, up 11%[2] - Initial jobless claims in the U.S. decreased by 1,000 to 209,000, slightly above Bloomberg's forecast of 206,000[2] Industry Developments - The Hang Seng Healthcare Index fell by 0.8%, with recent trading in pharmaceutical stocks being relatively quiet[3] - Inpharmatica (3696 HK) surged by 9.7% after announcing promising results for its oral GIPR antagonist ISM0676, achieving a weight loss effect of up to 31.3% in trials[3] Energy and Utilities - New energy and utility stocks showed mixed performance, with CGN Mining (1164 HK) rising by 3.3% as uranium prices approached a two-year high of $98[4] - Companies like China Everbright Environment (257 HK) and Beijing Enterprises Water Group (371 HK) saw stock increases between 1.1% and 4.5%[4] Consumer Sector - The wholesale price of Moutai has rebounded, leading to an 8.6% surge in Moutai's stock (600519 CH)[4] - Qingdao Beer (168 HK), China Resources Beer (291 HK), and Budweiser (1876 HK) stocks rose by 3% to 5% following positive trends in the A-share liquor sector[4]

Market Overview - On January 30, the A-share market experienced an overall decline, with the Shanghai Composite Index closing at 4117.95 points, down 0.96%, and the Shenzhen Component Index closing at 14205.89 points, down 0.66%. The ChiNext Index, however, rose by 1.27% to close at 3346.36 points. The total trading volume for both markets was 283.55 billion yuan, a decrease of 39.44 billion yuan from the previous trading day [1]. Capital Flow - The net outflow of main funds from the Shanghai and Shenzhen markets exceeded 54 billion yuan, with an opening net outflow of 24.87 billion yuan and a closing net outflow of 4.098 billion yuan, totaling 54.013 billion yuan for the day [2]. - Over the last five trading days, the main funds have consistently shown a net outflow, with the highest recorded outflow of 75.71 billion yuan on January 26 [3]. Sector Performance - The ChiNext saw a significant net outflow of 15.67 billion yuan, while the CSI 300 index experienced a net outflow of 7.919 billion yuan on the same day [4]. - In terms of sector performance, the communication sector saw a net inflow of 14.231 billion yuan, while the computer and pharmaceutical sectors faced the largest outflows, with net outflows of 15.418 billion yuan and 10.197 billion yuan, respectively [6][7]. Individual Stock Activity - The top stocks with net inflows included Xinyi Silver and Yunnan Copper, with net purchases of 539.36 million yuan and 173.80 million yuan, respectively. Conversely, stocks like Hunan Gold and Tian Di Online faced significant net outflows, with -70.3878 million yuan and -10.7999 million yuan, respectively [8][10]. - Institutional interest was noted in several stocks, with Huafang Co. receiving a "Buy" rating from UBS with a target price of 45 yuan, representing a potential upside of 56.52% from its latest closing price of 28.75 yuan [11].

1月27日，科技板块走势分化，固态电池板块持续调整，CPO概念逆势走强。从指数层面看，创业板成长指数上涨0.3%， 创业板指数下跌0.1%，创业板中盘200指数下跌4.1%。 兴业证券认为，随着A股上市公司年报预告进入披露高峰，叠加北美科技巨头财报集中披露，业绩对结构的影响或将更加 显著，继续聚焦基本面挖掘亮点。结合年报业绩预告线索与近期盈利预期边际上修情况，当前业绩具备亮点且本轮涨幅偏 低的行业主要集中在AI硬件、电池、医药、钢铁、非银等。 | | 创业板 | 创业板中盘 | 创业板成长 | | --- | --- | --- | --- | | | 指数 | 200指数 | 指数 | | 本周涨跌幅 | -0. 1% | -4. 1% | 0. 3% | | 指数滚动 市盈率 | 42. 3倍 | 113. 3倍 | 40. 5倍 | | 滚动市盈率 分位 | 39. 5% | 该指数2023年 11月15日发布 | 45. 4% | | 跟踪该 | 创业板ETF | 创业板200ETF | 创业板成长ETF 易方达 | | 指数的ETF | 易方达 | 易方达 | | | | (159915) | (1 ...